SGMS2 and central nervous system cancer: Basal SMS1 and SMS2 mRNA levels were evaluated in 6 human glioma cell lines, four responders and two non-responders (IC50 > 600 μM) to 2OHOA treatment and in one non-tumor cell line, (MRC-5).